Akoya Biosciences (AKYA)
(Delayed Data from NSDQ)
$3.80 USD
-0.02 (-0.52%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.80 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Akoya Biosciences (AKYA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.75 | $11.00 | $7.00 | 129.06% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Akoya Biosciences comes to $8.75. The forecasts range from a low of $7.00 to a high of $11.00. The average price target represents an increase of 129.06% from the last closing price of $3.82.
Analyst Price Targets (8 )
Broker Rating
Akoya Biosciences currently has an average brokerage recommendation (ABR) of 1.28 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.28 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 77.78% and 11.11% of all recommendations. A month ago, Strong Buy made up 77.78%, while Buy represented 11.11%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 6 | 6 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.28 | 1.28 | 1.28 | 1.31 | 1.31 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/12/2024 | Piper Sandler | David M Westenberg | Strong Buy | Strong Buy |
3/5/2024 | Canaccord Genuity | Kyle Mikson | Not Available | Strong Buy |
1/7/2024 | BTIG | Mark Massaro | Not Available | Strong Buy |
12/14/2023 | Guggenheim Securities | Subbu Nambi | Not Available | Hold |
11/13/2023 | Stephens | Mason Carrico | Strong Buy | Strong Buy |
11/9/2023 | Capital One Securities | Timothy Chiang | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.28 |
ABR (Last week) | 1.28 |
# of Recs in ABR | 9 |
Average Target Price | $8.75 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | -0.30 |